[go: up one dir, main page]

GB201209344D0 - Omega-6 enriched pufa phospholipids - Google Patents

Omega-6 enriched pufa phospholipids

Info

Publication number
GB201209344D0
GB201209344D0 GBGB1209344.9A GB201209344A GB201209344D0 GB 201209344 D0 GB201209344 D0 GB 201209344D0 GB 201209344 A GB201209344 A GB 201209344A GB 201209344 D0 GB201209344 D0 GB 201209344D0
Authority
GB
United Kingdom
Prior art keywords
phospholipids
omega
dgla
pufa
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1209344.9A
Other versions
GB2504061A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Priority to GB1209344.9A priority Critical patent/GB2504061A/en
Publication of GB201209344D0 publication Critical patent/GB201209344D0/en
Publication of GB2504061A publication Critical patent/GB2504061A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Insects & Arthropods (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical formulations comprise dihomo gamma linolenic acid (DGLA) or any appropriate metabolite or derivative e.g. 15-hydroxy-DGLA and krill oil (KO). They may be used for the treatment of a wide range of diseases and disorders. They may also be taken as a general nutritional supplement.
GB1209344.9A 2012-05-25 2012-05-25 Omega-6 Enriched PUFA Phospholipids Withdrawn GB2504061A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1209344.9A GB2504061A (en) 2012-05-25 2012-05-25 Omega-6 Enriched PUFA Phospholipids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1209344.9A GB2504061A (en) 2012-05-25 2012-05-25 Omega-6 Enriched PUFA Phospholipids

Publications (2)

Publication Number Publication Date
GB201209344D0 true GB201209344D0 (en) 2012-07-11
GB2504061A GB2504061A (en) 2014-01-22

Family

ID=46545984

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1209344.9A Withdrawn GB2504061A (en) 2012-05-25 2012-05-25 Omega-6 Enriched PUFA Phospholipids

Country Status (1)

Country Link
GB (1) GB2504061A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072959A (en) 2014-06-04 2017-08-18 尊严科学有限公司 Medical composition comprising two high acid and gamma-linolenics (DGLA) with and application thereof
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666447B2 (en) * 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US9107891B2 (en) * 2011-06-29 2015-08-18 Nippon Suisan Kaisha, Ltd. Method for alleviating fear memory

Also Published As

Publication number Publication date
GB2504061A (en) 2014-01-22

Similar Documents

Publication Publication Date Title
MX2016004487A (en) Enteric soft capsules comprising polyunsaturated fatty acids.
ES3030658T3 (en) Lipid nanoparticle formulations for crispr/cas components
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
ES2666322T3 (en) Pharmaceutical compositions for the treatment of muscular disorders
PH12018500090A1 (en) Nutritional compositions and methods for promoting cognitive development
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
EP3500291A4 (en) Formulations for oral administration of active agents
TW201613632A (en) Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction
TR201821157T4 (en) ORAL APPLICATION SOLID COMPOSITION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT AND VITAMIN D.
WO2014137797A3 (en) Stable glucokinase activator compositions
MX2022014682A (en) Compositions comprising vitamins and their use.
AR100028A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING ESTEARIDÓNIC ACID
HK1246653A1 (en) Onapristone extended-release compositions and methods
GB201209344D0 (en) Omega-6 enriched pufa phospholipids
WO2014003950A3 (en) Selenium containing nucleosides as nutritional supplements
AU2012386215A8 (en) Pharmaceutical composition of milk fat globules (MFGs) zinc free
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
EP3270883A4 (en) Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
MX361765B (en) Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration.
HK40101429A (en) Formulations for oral administration of active agents

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)